MedTrace Logo

Evaluation of Treatment Safety in Patients With Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey

NCT04594915 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1053

Last updated 2023-07-03

No results posted yet for this study

Summary

This is a national, multi-center, prospective study to evaluate the safety of Edoxaban in patients diagnosed with AF who are currently using Edoxaban for stroke prevention.

The primary objective:

* To evaluate safety of Edoxaban treatment in patients with atrial fibrillation (AF) on Edoxaban therapy in routine clinical practice in Turkey.

Conditions

Interventions

DRUG

Edoxaban

Edoxaban according to Package Information (Summary of Product Characteristics \[SmPC\]).

Sponsors & Collaborators

  • Daiichi Sankyo

    collaborator INDUSTRY

  • Daiichi Sankyo Turkey, a Daiichi Sankyo Company

    lead INDUSTRY

Principal Investigators

  • Clinical Director · Daiichi Sankyo Turkey, a Daiichi Sankyo Company

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-14
Primary Completion
2023-06-21
Completion
2023-06-21
FDA Drug
Yes

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04594915 on ClinicalTrials.gov